Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T15:45:35.213Z.
Calculation as of: 2026-10-06T15:45:35.213Z.
Quote observation: 2026-10-06T15:41:36.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 83c64da899843448fde498cf5e629ee28b7cf55c7878198a0aebccb75d14602d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2022-05-16.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
PRICE/FCF RATIO AVG TTM
N/A
PRICE/FCF RATIO AVG 3Y
N/A
PRICE/FCF RATIO AVG 5Y
N/A
PRICE/FCF RATIO AVG 10Y
N/A
PRICE/FCF RATIO AVG 15Y
N/A
PRICE/FCF RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Aspire Biopharma Holdings, Inc.
Market Cap
$1.04M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.10M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$873508.00
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.20M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$845829.00
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | $1.04M | N/A | N/A | N/A | N/A |
| Clearmind Medicine Inc. (CMND)vs › | $1.07M | N/A | N/A | N/A | N/A |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.10M | N/A | N/A | N/A | N/A |
| IM Cannabis Corp. (IMCC)vs › | $1.15M | N/A | 3.00 | 2.75 | 2.75 |
| Propanc Biopharma, Inc. (PPCB)vs › | $1.17M | N/A | N/A | N/A | N/A |
| Bone Biologics Corporation (BBLG)vs › | $873508.00 | N/A | N/A | N/A | N/A |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.20M | N/A | N/A | N/A | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $861994.00 | N/A | N/A | N/A | N/A |
| Decoy Therapeutics Inc. (DCOY)vs › | $845829.00 | N/A | N/A | N/A | N/A |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $827771.00 | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PRICE/FCF RATIO |
|---|---|
| 2022-05-16 | 60609.91 |
| 2022-05-13 | 60549.06 |
| 2022-05-12 | 60652.51 |
| 2022-05-11 | 60609.91 |
| 2022-05-10 | 60670.76 |
| 2022-05-09 | 60731.62 |
| 2022-05-06 | 60731.62 |
| 2022-05-05 | 61035.88 |
| 2022-05-04 | 60731.62 |
| 2022-05-03 | 60731.62 |
| 2022-05-02 | 60944.60 |
| 2022-04-29 | 60731.62 |
| 2022-04-28 | 60762.04 |
| 2022-04-27 | 60737.70 |
| 2022-04-26 | 60731.62 |
| 2022-04-25 | 60853.32 |
| 2022-04-22 | 60975.03 |
| 2022-04-21 | 60865.49 |
| 2022-04-20 | 60908.09 |
| 2022-04-19 | 60962.86 |
| 2022-04-18 | 60975.03 |
| 2022-04-14 | 60853.32 |
| 2022-04-13 | 60853.32 |
| 2022-04-12 | 60792.47 |
| 2022-04-11 | 60792.47 |
